Dan Streblow

Professor
Dan Streblow obtained his BS and Ph.D from University of Wisconsin, Madison where he studied HIV viral pathogenesis.   In 1997 he joined Jay Nelson’s lab as a Postdoctoral Fellow and in 2001 became a faculty member where he was engaged in research and teaching of graduate and medical students. He is a Professor at the Vaccine and Gene Therapy Institute with faculty positions in the Division of Pathology and Microbiology, ONPRC. During the SARS-Cov2 pandemic, Dan was instrumental in helping establish a clinical diagnostic laboratory at OHSU for the in-house detection of COVID-19. Currently Dan’s research interests focus on several viral systems including COVID-19, numerous Alphaviruses and CMV. The Streblow lab has been involved in the development of CMV vaccine vectors in mouse and rhesus-CMVs as well as a number of models to help determine the mechanisms of CMV-accelerated solid organ and bone marrow graft rejection. Dan has generated infection models for Zika virus, chikungunya virus (CHIKV) and Mayaro virus (MAYV) to characterize alphavirus infection and define the immune responses to the virus infection.  Overall, Dan’s focus on new and emerging DNA and RNA viruses continues to identify key host and viral factors involved in pathogenesis.

Whitney Weber

PhD Student
Whitney is an Oregon native and received her B.S. degree in Microbiology from Oregon State University in 2018. She joined the Streblow Lab in March 2021. She is currently a PhD candidate in OHSU’s program in Biomedical Sciences (PBMS) and her research focuses on vaccine-elicited or infection induced cross-reactive immunity to emerging alphaviruses. Her dissertation work has included exploration of Mayaro virus pathogenesis and immunity in rhesus macaques as well as characterization of cross-protective alphavirus vaccines. Whitney hopes to complete her PhD by the end of 2024 and plans to pursue roles in vaccine development in industry

Zach Streblow

Research Assistant II
I recently received my BS degree in BioHealth Sciences at Oregon State University in the Spring of 2022. Since then, I have been working as a research assistant with a focus on the discovery of antiviral drugs against emerging infectious viruses. Working with many collaborators, I perform mainly cell-based assays to determine the efficacy of potential compounds. Through this testing we have been able to identify potent antiviral drugs for chikungunya virus and other alphaviruses. With this experience, I hope to pursue a career in medicine and focus on translating this research into effective treatments for patients affected by infectious viruses. 

As a lifelong Oregon resident, outside the lab I am interested in hiking, kayaking, and recreational sports. Catch me spiking on the volleyball court at the annual West Campus tournament!

Takeshi Ando

Staff Scientist
I originally came from Japan to OHSU in 1992 as a visiting assistant professor of clinical immunogenetics, studying mechanisms of calcineurin inhibitors (immunosuppressants cyclosporine and tacrolimus) induced nephrotoxicity. My education was all done in Japan (BS in Chemistry, The University of Tokyo, PhD in Bio-organic chemistry, The University of Tokyo, MD from The University of Osaka). I work in Streblow lab as a microsurgeon to perform rodent heterotopic heart transplant surgeries, in vivo mice experiments and morphological analysis of those tissue histology. I am interested in animal models to study mechanisms of CMV reactivation, CMV accelerated chronic transplant rejection, cardiac transplant ischemia/reperfusion injuries. In my spare time, I love listening to classical music.

Sam Medica

PhD Student
Sam earned his B.S. in Integrative Biology from Oregon State University in 2018 and is currently pursuing a Ph.D. in the laboratory of Dr. Daniel Streblow. His research focus revolves around deciphering the mechanisms mediating human cytomegalovirus (HCMV) latency and reactivation. In particular, Sam's work delves into understanding the role of the viral chemokine receptor US28 during HCMV infection. Understanding the processes which drive the complex interplay between latent and lytic infection is critical for the development of novel treatments and interventions against HCMV associated disease. Outside of the laboratory, Sam enjoys playing golf, working on cars, and exploring the landscapes of the Pacific Northwest.

Patsy Smith

Senior Research Associate II
I moved from Fred Hutchinson Cancer Research Center to join the Nelson group in 1992 and  became part of the Streblow team when Dan joined as a post doc.  My training was initially in herpes virology, molecular biology and microscopy.  Over the years, through many and varied projects, I have become a bit of a jack-of-all-trades in the lab, stepping in when and where ever I’m needed, including lab management lab duties.  Outside activities include raising and showing corgis, hiking and enjoying time at my cabin on the Metolius river. 

Gauthami Sulgey

Post Doctoral Scholar
I wrapped up my Master's in Biochemistry and then dove into the world of research as a research fellow at Ella Foundation, a R&D facility of Bharat Biotech in Hyderabad, India. While there, I got the chance to pursue my Ph.D., and I focused on the intriguing topic of HCMV immune evasion. But that's not all – besides my doctoral work, I had some cool experiences working on various viral vaccine projects, which really broadened my horizons. I even had a brief stint at the National Institute of Animal Biotechnology in Hyderabad, where I worked to develop a SARS-CoV2 replicon.

I recently joined the Streblow Lab as a postdoctoral scholar, where I am currently working to test antiviral compounds that are effective against HCMV and also to identify the mechanism of action of the compound.

When I'm not wearing my science hat, I'm spend time with my husband and our 4-year-old kid. And, I'm pretty excited about exploring more of what Portland has to offer in my free time.

Craig Kreklywich

Senior Research Associate II
Craig came to OHSU from a Biotech company in1999. He joined the Orloff lab where the focus was on CMV infection and its effect on the longevity of solid organ transplants in recipients. After collaborating with Dr. Streblow for eight years, Craig became a member of his lab in 2007 and continued to work on transplant rejection and new and emerging viruses.